Abstract: Vehicles and systems and methods for determining a viewing direction of a user are disclosed. In one embodiment, a system for detecting a viewing direction of a user includes a marker arranged at a fixed location, and an optical assembly. The optical assembly includes a first optical sensor arranged to view the marker, and a second optical sensor arranged to view the user. The first optical sensor detects the marker for determining a spatial location of the optical assembly with respect to the marker, and the second optical sensor detects an eye of the user for determining an eye angle of the user.

Abstract: A deposit-inhibiting composition has been developed that provides an advantageous reduction in the deposits of solids in the near wellbore region, and in equipment and lines used for crude oil production and processing. The deposit-inhibiting compositions contain a surface-active component comprising a phosphate ester component, a sulfurized olefin component, or a combination thereof; a polyalkylene ester; and an imidazoline compound. The deposit-inhibiting compositions are particularly useful as flow agents for delivery to a subsea wellhead via an umbilical line.

Abstract: A method for range detection is described. The method includes segmenting an image into one or more segmentation blobs captured by a monocular camera of an ego vehicle. The method includes focusing on pixels forming a selected segmentation blob of the one or more segment blobs. The method also includes determining a distance to the selected segmentation blob according to a focus function value of the monocular camera of the ego vehicle.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: A method for providing targeted pre-caching of data is disclosed. The method includes receiving a user login that includes an account identifier; automatically identifying a subset of the data previously accessed by the user using an activity log and the account identifier; generating a copy of the subset of the data; associating the copy with the subset of the data by linking the subset of the data with the copy; and storing the copy in a temporary file store. The method further includes receiving a request from the user for the subset of the data and displaying the copy on a graphical user interface.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Methods for estimating the solvency potential for various chemical additives used for asphaltene deposit remediation or inhibition have been developed. These methods can be used for remediating or inhibiting asphaltene deposition in various applications including upstream production (e.g., near-wellbore, downhole, flow-lines, separators), midstream processes (e.g., pipe lines, transport, and storage), and downstream (e.g., hydrocarbon refining).

Abstract: Disclosed are example embodiments of a system of retinal three-dimensional (3D) imaging. The system of retinal 3D imaging includes an image sensor within a light path and a reimaging corrective optics module within the light path. The system of retinal 3D imaging also includes an objective lens in the light path and a baffle-and-illumination module in the light path. In an aspect, the reimaging corrective optics module is in front of the image sensor, the objective lens is in front of the reimaging corrective optics module, and the baffle-and-illumination module is between the objective lens and the reimaging corrective optics module.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Various embodiments for eye imaging, screening, diagnosis, and monitoring are provided. Some embodiments comprise systems for retinal imaging capable of capturing multiple high resolution images using multiple quick succession flashes. The images can be combined to provide for a complete image of the retina of a target FOV without corneal reflections. In some embodiments, a system for retinal imaging can utilize an optical design pupil layout that allocates a large area for the path of imaging rays on the eye pupil by using a narrow buffer area. In other embodiments, a system for retinal imaging can comprise a main device, including an imaging and sensing device, and a robotic system, including an eye tracker and/or sensors, wherein the robotic system is capable of automatically aligning the main device and selecting an optimal imaging mode by detecting a pupil size of an eye and is combined with an AI analysis tool.

Abstract: Vehicles and systems and methods for determining a viewing direction of a user are disclosed. In one embodiment, a system for detecting a viewing direction of a user includes a marker arranged at a fixed location, and an optical assembly. The optical assembly includes a first optical sensor arranged to view the marker, and a second optical sensor arranged to view the user. The first optical sensor detects the marker for determining a spatial location of the optical assembly with respect to the marker, and the second optical sensor detects an eye of the user for determining an eye angle of the user.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: A method for providing targeted pre-caching of data is disclosed. The method includes receiving a user login that includes an account identifier; automatically identifying a subset of the data previously accessed by the user using an activity log and the account identifier; generating a copy of the subset of the data; associating the copy with the subset of the data by linking the subset of the data with the copy; and storing the copy in a temporary file store. The method further includes receiving a request from the user for the subset of the data and displaying the copy on a graphical user interface.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: The present disclosure pertains to a system for facilitating computer-assisted care for patients, including, for example, skilled nursing facility (SNF) patients at risk of clinical deterioration and/or in need of medical intervention relative to a larger SNF patient population. In some embodiments, the system determines care information scores for SNF patients using a first set of severity weights associated with individual components of the care information. The system determines SNF enhancement scores for the individual patients using a second set of severity weights associated with individual components of collected SNF enhancement information, wherein the second set of severity weights are heavier than the first set of severity weights such that the enhancement scores are weighted more heavily than the care information scores.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.